Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1/2 1

Status

Completed 13Recruiting 7Not yet recruiting 4Active not recruiting 3Unknown 2

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 7

Sponsor

Cancer Type

Lymphoid 7Sarcoma 1Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 7Prostatic Neoplasms 5Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Lymphoma, Follicular 2Leukemia, Biphenotypic, Acute 2Endometrial Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Neoadjuvant Therapy 1Myasthenia Gravis 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, B-Cell 1Heart Failure 1Dendritic Cell Sarcoma, Interdigitating 1Colorectal Neoplasms 1Cardiotoxicity 1Carcinoma, Non-Small-Cell Lung 1Bulbo-Spinal Atrophy, X-Linked 1Brain Neoplasms 1Biliary Tract Neoplasms 1Adrenal Insufficiency 1

Interventions

Rituximab 39Cyclophosphamide 35Magnetic Resonance Spectroscopy 22Specimen Handling 20Doxorubicin 18polatuzumab vedotin 17Prednisone 17Lenalidomide 15Biopsy 15fludarabine 13Oxaliplatin 13Gemcitabine 13zanubrutinib 11Vincristine 11Immunotherapy, Adoptive 10Etoposide 10glofitamab 9axicabtagene ciloleucel 7Prednisolone 7obinutuzumab 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Leukapheresis 6Injections 6Ifosfamide 6Bendamustine Hydrochloride 6loncastuximab tesirine 5ibrutinib 5acalabrutinib 5Carboplatin 5CT-P10 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Large B-Cell, Diffuse × Prednisolone × Clear all
NCT06717347 2026-05-29

MK-2140-010

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,046 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-05-29

MK-2140-011

Merck Sharp & Dohme LLC

Phase 2 Recruiting
594 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06091865 2026-05-15

OLYMPIA-3

Regeneron Pharmaceuticals

Phase 3 Recruiting
904 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Recruiting
41 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06220032 2026-01-05

HO170DLBCL

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 3 Recruiting
324 enrolled
LymphoidSarcoma

Heart Failure, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating, Cardiotoxicity

NCT06594640 2025-05-14

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Institute of Hematology & Blood Diseases Hospital, China

Phase 1/2 Recruiting
108 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03899337 2023-01-09

STELLAR

University of Birmingham

Phase 2 Recruiting
105 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡